BeOne Medicines AG

Total Valuation

BeOne Medicines AG carries a market capitalization of 40.13B, placing it among publicly traded companies globally. Its enterprise value stands at 414.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

BeOne Medicines AG currently has 1.47B shares outstanding.

Valuation Ratios

BeOne Medicines AG trades at a trailing price-to-earnings ratio of 48.18. The price-to-sales ratio is 5.15, and the price-to-book ratio stands at 80.95.

Enterprise Valuation

On an enterprise value basis, BeOne Medicines AG trades at an EV/EBITDA multiple of 384.84 and an EV/FCF ratio of 242.05. The EV/Sales ratio of 67.69 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 449.43 provides insight into valuation relative to core operating earnings.

Financial Position

BeOne Medicines AG maintains a current ratio of 3.40, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.10, indicating elevated leverage, while an interest coverage ratio of 14.84 demonstrates strong ability to service its debt obligations.

Financial Efficiency

BeOne Medicines AG posts a return on equity of 14.66 and a return on invested capital of 12.18.

Taxes

Over the trailing twelve months, BeOne Medicines AG has paid 212.37M in income taxes, reflecting an effective tax rate of 24.46.

Stock Price Statistics

BeOne Medicines AG's stock has gained approximately 17.86936% over the past 52 weeks. The 50-day moving average sits at 360.65, while the 200-day moving average is 322.87.

Income Statement

Over the trailing twelve months, BeOne Medicines AG generated 6.13B in revenue and converted that into 655.71M in net income, yielding earnings per share of 5.68. EBITDA reached 1.08B, while operating income came in at 923.10M.

Balance Sheet

BeOne Medicines AG holds 5.10B in cash and equivalents against 1.14B in total debt, resulting in a net debt position of -4.02B. Total book value stands at 5.17B, with working capital of 5.10B providing operational flexibility.

Cash Flow

BeOne Medicines AG produced 1.48B in operating cash flow over the past twelve months. After subtracting -175.08M in capital expenditures, free cash flow totaled 1.31B - equivalent to 11.81 per share.

Margins

BeOne Medicines AG operates with a gross margin of 88.89, reflecting its pricing power and cost economics. The operating margin of 15.06 and net profit margin of 10.70 provide insight into operational efficiency.

Dividends & Yields

Scores

BeOne Medicines AG posts an Altman Z-Score of 63.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.